Skip to main content
. 2020 Oct 30;48(5):1650–1657. doi: 10.1007/s00259-020-05082-5

Fig. 3.

Fig. 3

Prediction of survival rate among studied mCRPC patients based on serum Hb levels prior to the therapy initiation with 7400 MBq PSMA-RLT every 4 weeks. Patients with basal Hb levels within normal range had significantly longer rate of survival than patients with reduced basal Hb levels prior to the beginning of the PSMA-RLT (median survival not reached vs. 89 weeks, P = 0.016). Patients with basal Hb levels < 10.45 g/dL had significantly shorter survival rate than patients with basal Hb levels > 10.45 g/dL prior to the PSMA-RLT (median survival 47 weeks vs. median survival not reached, P < 0.001)